MLYS — Mineralys Therapeutics Share News
0.000.00%
Brief: Mineralys Therapeutics Inc Says Topline Data From Trial Are Expected In First Half Of 2024
U.S. RESEARCH ROUNDUP-Adobe, Five Below, Lennar
Brief: Mineralys Therapeutics Reports Q4 And Full Year 2022 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-BlackSky, Squarespace, Virax Biolabs
Credit Suisse initiates coverage on Mineralys with 'outperform' rating
Brief: Mineralys Therapeutics Says Positive Lorundrostat Results From The Phase 2 Target-Htn Trial At ACC.23/Wcc
Brief: Mineralys Therapeutics Announces Closing Of Initial Public Offering
Brief: Mineralys Therapeutics Shares Open 31.9% Above IPO Price In Nasdaq Debut